Chong Kun Dang Pharmaceutical Corp. is one of leading Korean pharmaceutical manufacturers and has a great strength on domestic sales not only with prescription drugs indicated for anti-hypertension, anti-hyperlipidemia and anti-diabetics but also with OTC drugs such as Penzal, Prefemine, Modcol and consumer health such as insecticides, hairdye, etc.
Chong Kun Dang has a complete portfolio of prescription pharmaceutical products for the entire segment and therapeutic classes, supported not only by own-developed NCE drugs
Camptobell as an anticancer and anti-diabetic, Duvie, but also anti-hypertension Dilatrend, Telminuvo, anti-hyperlipidemia Lipilou, and immunosuppressant Tacrbell.
Chong Kun Dang’s OTC drugs consist of products known for their therapeutic benefits, as well as supplements and other preventive products. Penzal which is best-seller for headache in Korea, Zelcom as No.1 antithelmintic, and fast-effective digestive Sok-chung drink carry strong brand names that have dominated the market over the past few decades. In recent days, some of Chong Kun Dang’s preventive OTCs are positioning to advance women’s health such as Prefemine for premenstrual syndrome and Simidona for menopause symptom, Bolgre for iron supplements.
Chong Kun Dang provides high-quality healthcare supplements with preventive benefits including prebiotics complex Prelacto and Premium Omega-3+vitamin series caring for modern people in their busy life.
Chong Kun Dang’s selection of healthy beverage products range from Sok-chung cool, and Ja-Whang, San-e-nun-Sam with red-ginseng based healthy drink to insecticides Jjong aerosol.
Global business presence
Chong Kun Dang is expanding the market in worldwide with strategic products in immunosuppressant, anti-cancers and antibiotics. In order to grow strength in Globalization (Globalization + Localization), Chong Kun Dang opened representative office in Vietnam since 2012 and established Joint Venture company in Indonesia in 2015.
Chong Kun Dang’s manufacturing site in CheonAn city supply quality prescribed products meeting with global standard into worldwide as Japan, China, South-east Asian, MENA and African countries. In recent, it is being strengthen to dominant market share in ASEAN region through Indonesian JV Company, VN rep. office and further footholds.
In September 2015, Chong Kun Dang has established the joint venture company PT CKD OTTO Pharmaceuticals with PT OTTO Pharmaceutical Ltd., which is one of leading local pharmaceutical companies in Indonesia. In the future, PT CKD OTTO as a production base not only for domestic market, but
only for near Asian, MENA and EU countries, will manufacture and distribute anti-cancer drugs such as Belloxa, Gemtan, etc. through which Chong Kun Dang has global competitiveness.
Vietnam Rep. Office
Since Chong Kun Dang’s Vietnam representative office has been established in 2012, it has been raised company awareness in domestic by expanding the pipeline of prescription drugs as well as health care products. Through various promotion activity, oncology products (Belloxa, Gemtan), anti-hypertensives (Candemore plus), antibiotics (Kmoxilin) and various health care products including red-ginseng liquid, collagen capsule, probiotics, etc are being distributed in nationwide.
Licensing and Tech Transfer
Chong Kun Dang is focused on in-licensing novel drugs which offers better solution for chronic disorders such as diabetes and cardiovascular diseases, as well as for anti-cancer therapies and neurological diseases with high medical unmet needs. Having developed Duvie®, the new drug for type II diabetes, Chong Kun Dang is actively expanding its global presence with the best-in-class anti-cancer pipelines (CKD-516 and CKD-581) and dyslipidemia therapy (CKD-519), starting from the neighboring Asian markets. Further, Chong Kun Dang has an in-house technology platform for HDAC6-selective inhibitors which provides the novel mechanism of action. We are enthusiastically preparing for the global market entry via strategic business diversification, specifically targeting auto-immune diseases, neurological disorders, and cancer.
Supported by its long presence in Korean pharmaceutical industry and strong sales and marketing capacity, Chong Kun Dang is involved in numerous business alliance relationships with the most prestigious multinational companies in various fields. Over the last decade, Chong Kun Dang has formed the partnership with MNCs such as Bayer, Roche, Allergan, Pfizer, and MSD and, as a result, Chong Kun Dang has an unrivaled leadership in the local market enhanced by its robust product portfolio which now covers a broad range of therapeutic classes with innovative, outstanding drugs. Chong Kun Dang will continue to work towards mutual development through global business partnering.
Avelox®, Ciprobay®, Ciprouro®
Hospital Solns, Nutriflex®, Lipidem®
Dilatrend®, Tamiflu®, Kytril®, etc
Januvia® Family, Vytorin®, Atozet®